ACE2 is considered a new therapeutic strategy for DKD due to its renoprotective effect by converting angiotensin II (Ang II) to angiotensin 1–7 (Ang 1–7), which acts as a vasodilator, anti-inflammatory, anti-fibrotic, and anti-proliferation agent via its specific Mas receptor to counteract the side effects of Ang II (25, 26). The gene discussed is AGT; the disease is diabetic kidney disease.